Latest information on COVID-19
Unraveling Leukemia Heterogeneity Using Single-cell Studies for Clinical Translation
Feb 01, 2021 (Mon) | 12:00 PM -1:00 PM
Webinar link will be sent after registration. : Virtual Event, CA
Among children with B-cell progenitor acute lymphoblastic leukemia (ALL), the most common kind of childhood cancer, 15% of children will relapse after initially responding to standard therapies, and 50% of children who relapse will die, making relapsed ALL the second-leading cause of cancer-related death in children. Even with the emergence of novel immunotherapies, including chimeric antigen receptor (CAR) T-cells, at least 40% of children with ALL who initially respond to these novel therapies will still go on to relapse. In this talk, Dr. Kara Davis will discuss the use of a single-cell mass cytometry, or CyTOF, to identify cells associated with relapse from diagnostic patient samples.
Department: Stanford Maternal and Child Health Research Institute
Contact: Roxanna Van Norman | 6504985444 | email@example.com